|
Efficacy and toxicity of HLX07 as a new anti-EGFR monoclonal antibody for epithelial cancers. |
|
|
Employment - Helix Biotech |
Leadership - Helix Biotech |
Stock and Other Ownership Interests - Helix Biotech |
Consulting or Advisory Role - Helix Biotech |
Speakers' Bureau - Helix Biotech |
Research Funding - Helix Biotech |
Patents, Royalties, Other Intellectual Property - Henlix Biotech co., LTD |
Expert Testimony - Helix Biotech |
Travel, Accommodations, Expenses - Helix Biotech |
|
|
Employment - Helix Biotech |
Leadership - Helix Biotech |
Stock and Other Ownership Interests - Helix Biotech |
Speakers' Bureau - Helix Biotech |
Research Funding - Helix Biotech |
Patents, Royalties, Other Intellectual Property - Henlix Biotech co., LTD |
Expert Testimony - Helix Biotech |
Travel, Accommodations, Expenses - Helix Biotech |
|
|
Employment - Helix Biotech |
Leadership - Helix Biotech |
Stock and Other Ownership Interests - Helix Biotech |
Consulting or Advisory Role - Helix Biotech |
Speakers' Bureau - Helix Biotech |
Research Funding - Helix Biotech |
Patents, Royalties, Other Intellectual Property - Henlix Biotech co., LTD |
Expert Testimony - Helix Biotech |
Travel, Accommodations, Expenses - Helix Biotech |
|
|
No Relationships to Disclose |